Endo pharma slalom8/6/2023 Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated, global biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. This press release contains forward-looking statements that involve substantial risks and uncertainties. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Germany (Heidelberg, Berlin and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey). ![]() Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Poster, Thursday, June 15, 12:30 - 1:30 pm (CDT)Īscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients’ lives. Poster, Thursday, June 15, 12:30 – 1:30 pm (CDT)ĭesign of the New InsiGHTS Trial: A Multicenter, Phase 2, Randomized, Open-Label, Active Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Lonapegsomatropin in Prepubertal Individuals with Turner Syndrome Subanalysis by Tanner Stage in Phase 3 Trials in Children and Adolescents with Growth Hormone Deficiency Treated with Lonapegsomatropin Late Breaker: Poster, Saturday, June 17, 1:00 – 2:00 pm (CDT) Prevalence of Comorbidities Among Treated and Untreated Adults with Suspected Growth Hormone Deficiency Poster, Thursday, Thursday, June 15, 12:30 - 1:30 pm (CDT) Significantly Improved Annual Height Velocity with Once-Weekly TransCon CNP in Children with Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial Oral presentation, Saturday, June 17, 4:30-4:45 pm (CDT))Ĭlinical and Economic Burden of Postsurgical Chronic Hypoparathyroidism: A U.S. Long-Term Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results from the Open-Label Extension of the PaTHway Phase 3 Trial In addition, Ascendis will host booth #1628, booth #1740, and two product theaters during ENDO 2023. Phase 3 Week 52 data for TransCon ™ PTH in adults with hypoparathyroidism selected for oral presentationĬOPENHAGEN, Denmark, J(GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome at ENDO 2023, the annual meeting of the Endocrine Society being held June 15-18 in Chicago.Īn oral presentation on Saturday, June 17, will feature Phase 3 Week 52 data for TransCon PTH in adults with hypoparathyroidism, and five additional poster presentations listed in the table below will showcase other Ascendis programs and data. ![]() Endocrinology clinical development progress and research i n growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |